Is Adagene Inc. (ADAG) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 13.8% / 30% | 63.6% / 30% | 0.0% / 30% | 3683.33% / 5% | ✗ NOT HALAL |
| DJIM | 13.8% / 33% | 63.6% / 33% | 0.0% / 33% | 3683.33% / 5% | ✗ NOT HALAL |
| MSCI | 20.7% / 33% | 95.4% / 33% | 0.0% / 33% | 3683.33% / 5% | ✗ NOT HALAL |
| S&P | 13.8% / 33% | 63.6% / 33% | 0.0% / 33% | 3683.33% / 5% | ✗ NOT HALAL |
| FTSE | 20.7% / 33% | 95.4% / 33% | 0.0% / 50% | 3683.33% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -32283.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -63.3% | |
| Return on Assets (ROA) | -24.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$30M |
| Free Cash Flow | -$30M |
| Total Debt | $18M |
| Debt-to-Equity | 18.1 |
| Current Ratio | 2.3 |
| Total Assets | $89M |
Price & Trading
| Last Close | $4.14 |
| 50-Day MA | $3.07 |
| 200-Day MA | $2.21 |
| Avg Volume | 183K |
| Beta | 0.8 |
|
52-Week Range
$1.30
| |
About Adagene Inc. (ADAG)
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Adagene Inc. (ADAG) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Adagene Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Adagene Inc.'s debt ratio?
Adagene Inc.'s debt ratio is 13.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 20.7%.
What are Adagene Inc.'s key financial metrics?
Adagene Inc. has a market capitalization of $178M, and revenue of $103,204. Return on equity stands at -63.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.